# Welcome to the 50<sup>th</sup> Annual General Meeting of Blackmores Limited


## Year in Review



# Christine Holgate CEO & Managing Director




# 10<sup>th</sup> year of record sales and profit



- Group Sales up 11% to \$261m
- Fourth Quarter record sales quarter, \$75m
- Another record profit year, \$27.8m
- Earnings per share growth of 1.6% to 165.8c
- Dividends of 127 cents, up 2.5%
- Most Trusted Brand in Australia, Thailand & Malaysia
- 102 new product launches and 43 product renovations
- Progressed launch in China
- Acquired BioCeuticals for \$39.2m




## Group sales performance





- Group sales increased by 11% to \$261m
- Australian sales of \$201m, +9% growth
- Asian sales of \$53m in AUD, +20% growth
- NZ sales of AU\$4.3m\*
- PAW sales up 129% on prior year to \$3.2m
   \*New operating model commenced May 2012


### Australian sales performance



- Sales of \$201m, +9% growth
  - Investment in advertising and channel promotions
- Launched into new categories natural pain cream, sports supplements and meal replacement smoothies
- Launched Blackmores Eco Krill, the only sustainably sourced krill oil which is certified by the Marine Stewardship Council
- Drove digital presence for engagement: launched MyBlackmores & App, 400k members to Blackmores Online
- Rolled out innovative new merchandising units into community pharmacies
- Awarded Most Trusted Brand, Employer of Choice and NSW Business of the Year

#### Asia growth continues






- Asia now represents 20% of Group sales and 26% of Group profit
- Sales growth of 20% in AUD (23% in constant currency) to \$53 million
- Strong growth in key markets: Thailand +26% and Malaysia +17% in local currency
- Solid growth in smaller markets of 25%
- New websites in Chinese, Korean & Thai with 65,000 Facebook fans in Asia
- Increased investment to support business development
- Launched into China in Q4 through a number of retail channels



## Profit performance



- Group NPAT increased by 2% to \$27.8m
  - Asia now contributes
    26% of group NPAT (up from 20% in FY11 and 10% in FY10)
- EBIT margin of 16.1%, solid performance considering:
  - Challenging Australian retail environment putting pressure on margins
  - Investment in growth opportunities particularly in Asia and supporting BioCeuticals acquisition
  - One-off expenses including legal fees and costs associated with supporting new organisation structure



#### Strong finish to FY12 - Fourth Quarter

- Group sales up 19%
- Australian Q4 sales up 17%

- Asian Q4 sales up 21%
- Strong Q4 profit result driven by a strong sales performance across all markets

Quarter 4 Segment Sales	2012 \$m	2011 \$m	Change	Quarter 4 P&L	2012 \$m	2011 \$m	Change
Australia	57.5	49.3	+17%	Group sales	74.6	62.6	+19%
Asia	14.5	12.0	+21%	EBITDA	13.2	12.1	+9%
Other	2.6	1.3	+102%	NPAT	7.8	7.1	+11%
Group sales	74.6	62.6	+19%				
8					BLACK	MORES	

#### Blackmores acquisition of FIT-BioCeuticals



- In July 2012, Blackmores acquired 100% of the share capital of FIT-BioCeuticals Limited, the leading brand of practitioner-only supplements in Australia
- FIT-BioCeuticals develops and markets a range of nutritional supplements to integrative medicine practitioners, natural health professionals, pharmacists and health food stores primarily in Australia and New Zealand
- Agreed purchase price was up to \$40 million and was fully debt funded from additional bank facilities
- In the 2011 financial year, the BioCeuticals group delivered sales of \$38 million and EBITDA of \$4.6 million

#### **About BioCeuticals**

- Founded in 1993 an Australian-owned, family company
- BioCeuticals a practitioner-only, nutraceutical brand (75%+ Sales)
- PharmaFoods Professional a pharmacy-only, nutraceutical brand
- IsoWhey a retail range of weight-loss products
- Hall Drug Technologies (HDT) development of ethical prescription-only products
- D'jeunesse a professional skincare range
- FIT-BioCeuticals boasts a team of 100+ employees with more than 50 qualified health practitioners including naturopaths, biochemists and medical doctors.



## Strategic rationale for acquisition

- Underpins our growth strategy recognising the importance of the Practitioner market in advising consumers
- The Practitioner market is a growing segment with strong margins, effective participation allows us to grow profitably close to our core.
- Unique cultural alignment
- Builds a Powerhouse of Natural Health Expertise 200 healthcare professionals in Group
- The business will operate as a stand-alone entity but will benefit from the resources of the broader Group
- Number One brand in retail market acquiring leading brand in practitioner market affirms Blackmores' position as the clear market leader in natural health in Australia





# Estimated Blackmores and BioCeuticals FY12 sales - together over \$300m




\$ million	Blackmores	BioCeuticals	Pro Forma FY12
Revenue	260.8	41.2	302
EBITDA	46.9	4.6	51



# First Quarter Results

## **First Quarter Results**

Q1	SALES	YEAR ON YEAR
Group	\$85.1m	+28%
Blackmores Australia	\$57.5m	+9%
Asia	\$13.9m	+14%
BioCeuticals	\$10.4m	+5%
PAW	\$1.0m	+93%
NZ	\$2.3m	+175%*
Group NPAT	\$7.8m	+0.2%




\*Reflecting new operating model



## First Quarter Highlights

- BioCeuticals successfully acquired for \$39.2m
- Blackmores Australia new marketing campaign
- China efforts begin including launch on CJO Shopping, roll-out in pharmacies and appointment of 60 new product advisors
- Investment in developing our Asia leadership team
- Launched over 40 new products across the group
- Successful Blackmores Sydney Running Festival, raising nearly \$2 million for charity
- Heart Research Institute honours Blackmores for commitment to young researchers





#### Blackmores announces Blackmores Institute

Blackmores Institute will be established with the purpose of becoming a centre of excellence in the field of natural health research and education.

This includes:

- Research funding
- Systematic reviews on natural medicines
- Prescribing guidelines
- Research symposia and conferences
- Research updates
- Education programs





#### Summary

- Blackmores Australia has had a strong start to the year in the context of the retail environment
- BioCeuticals a new platform for growth
- Asia continues to be a strategic area of growth, with significant opportunities
- Blackmores well positioned as world leader in natural health
- Profit is solid given high level of investment
- Directors remain confident Blackmores will continue to deliver strong returns to shareholders





## **Financial Performance**



**Chris Last** Chief Financial Officer



## Financial Summary – Profit & Loss

Income Statement	June 2012	June 2011	% Change
	\$m	\$m	
Sales	260.8	234.4	+11.3
Operating Expenses	<u>(213.9)</u>	<u>(187.8)</u>	+13.9
EBITDA	46.9	46.6	+0.6
Depreciation & Amortisation	<u>(4.9)</u>	<u>(4.5)</u>	
EBIT	42.0	42.1	-0.2
Interest & Tax	<u>(14.2)</u>	<u>(14.8)</u>	
Net profit after tax	27.8	27.3	+1.8
Earnings per share (c) - basic	165.8	163.2	+1.6


## Financial Summary - Balance Sheet & Cash Flows

	June 2012	June 2011	% Change
Net Assets (\$m)	86.3	79.1	+9.1
Net tangible assets per share (\$)	\$4.75	\$4.43	
Net debt (\$m)	33.0	29.8	+10.8
Gearing Ratio (%)	27.7%	27.4%	
Operating Cash Flow (\$m)	20.8	21.6	-3.6

# **Financial Summary - Key Ratios**

	June 2012	June 2011	% Change
EBIT Margin (%)	16.1%	17.9%	-1.8 pts
Net Interest Cover (times)	15.2 x	15.4 x	
Return on Equity (%)	32.2%	34.5%	-2.3 pts
Return on Assets (%)	25.6%	27.4%	-1.8 pts
Total Shareholder Return 1 July 2011 – 23 October 2012	28.6%		
21		BLACK	MORES

## Dividends



Dividends per share 4 Dividend payout ratio

Х




- Final dividend of 83¢ fully franked
- Total dividends for the year 127¢, up 2.5% on FY11
- Paid on 16 October 2012
- Dividend payout ratio of 76.6%
- Dividend Reinvestment Plan reactivated with a 5% discount – 28% take-up

#### **Debt Structure**

- The group's debt structure has materially changed as a result of the acquisition of BioCeuticals:
  - Debt increased by \$39m to fund the purchase price, plus \$1.4m for working capital adjustments
  - Gearing ratio (net debt / net debt + equity) increases from 28% to approx. 46%
- The Dividend Reinvestment Plan was reactivated for the final dividend with a 28% take-up, resulting in a \$4m cash saving
- BioCeuticals is earnings accretive in F13 even after debt servicing
- The Board and management have every confidence in the Group's ability to continue to comply with debt covenants




#### Performance Relative to Market – July 2011 to October 2012



#### **Financial Summary**


- Very positive sales performance and solid profit performance
- Strong balance sheet
- Low gearing ratio maintained, although increasing post acquisition
- Interest cover of 15.2 times
- Total dividend of 127 cents with a dividend payout ratio of 76.6%
- Total shareholder return of 29% since July 2011 superior return compared to All Ords

### **Formal Business**



## Marcus C. Blackmore AM

Chairman



#### Resolutions

- Remuneration Report
- Re-elect Mr Marcus Blackmore
- Re-elect Mr Brent Wallace
- Approval of Financial Assistance



## Resolution 1 – Remuneration Proxies

			% of all
Vote Type	Voted	% of Voted	securities
For	2,648,496	75%	16%
Against	548,216	15%	3%
Open-Usable - refer below	360,339	10%	2%
Total	3,557,051	100%	

Open-Usable Breakdown		
Chairman appointed as Proxy	194,692	5%
Others appointed as Proxy	165,647	5%



#### Resolutions

- Remuneration Report
- Re-elect Mr Marcus Blackmore
- Re-elect Mr Brent Wallace
- Approval of Financial Assistance



# Thank you

## Next AGM will be at the Blackmores Campus 22 October 2013

